The EPS beat vs consensus is modest and the company remains pre-revenue. The key catalyst is the upcoming FDA meeting and potential registration-enabling trial initiation in H2 2026. Monitor for FDA meeting minutes and trial design update expected in Q2 2026.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 27 $7.72entry
- T+1 · 7mo ago −3.63%α −3.14% · $7.44
- T+5 · 7mo ago −9.07%α −9.47% · $7.02
- T+20 · 6mo ago −12.44%α −17.39% · $6.76
- T+60 · 4mo ago −52.07%α −56.85% · $3.70
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fulcrum Therapeutics reported Q1 2026 net loss of $18.9M ($0.25 per share), slightly narrower than the consensus estimate of a $0.30 loss. The company highlighted positive clinical data for pociredir in sickle cell disease, plans to initiate a registration-enabling trial in H2 2026, and ended the quarter with $333.3M in cash, providing runway into 2029. CFO Alan Musso announced retirement later this year.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $18.9M ($0.25 per share) vs consensus estimate of $0.30 loss per share
- Cash, cash equivalents and marketable securities of $333.3M as of March 31, 2026, down from $352.3M at year-end 2025
- Positive clinical data from Phase 1b PIONEER trial of pociredir in sickle cell disease presented in Q1 2026
- Plans to initiate a potential registration-enabling trial for pociredir in H2 2026 pending FDA feedback
- CFO Alan Musso plans to retire later this year; search for successor initiated
- Cash runway guidance extended into 2029
Financial Impact
Net loss of $18.9M, slightly better than consensus; cash burn of $19.0M in Q1; no revenue reported
Risk Factors
- Clinical-stage biotech with no approved products or revenue; depends on successful clinical development and regulatory approval of pociredir
- CFO retirement introduces leadership transition risk
- Cash burn rate may require additional financing before reaching profitability
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281455 |
Track record
23 reports on FULC
6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
- Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers